Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Join Profs. Brusselle and Backer as they discuss the concept of disease modification in asthma. Join them as they highlight  the concept of disease modification in severe asthma, how it can be defined and objectively assessed, and the benefits for the patient when disease modification is a treatment target.   ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.   This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures:   Dr. Vibeke Backer: has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. Dr. Guy Bruselle:  has received grants from Merck Sharp & Dohme and has recevied lecturer/consultant fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Sanofi   © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2503097 - 1.0 - 01/2026 MAT-US-2600873 v1.0 - P Expiration Date: 01/28/2028